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Abstract
Background: As a complex nervous system disease, migraine causes severe healthy and social issues worldwide.
Valproate (VPA) is a widely used treatment agent against seizures and bipolar disorder, and its function to alleviate
damage due to migraine has also been verified in clinical investigations. However, the mechanism underlying the
protective effect of VPA against migraine remains poorly revealed. In the current study, the major purpose was to
uncover the mechanism which drove VPA to antagonize migraine.
Methods: Nitroglycerin (NTG) was employed to induce a migraine model in rats and the migraine animals were
exposed to treatment of VPA of different doses. Thereafter, the levels of indicators related to oxidative stress were
measured and used to evaluate the anti-oxidant potential of VPA. The expression of calcitonin gene-related peptide
(CGRP) and c-Fos was also quantified with ELISA and immunohistochemistry, respectively. Western blotting and
electrophoretic mobility shift assays (EMSA) were conducted to explore the effect of VPA treatment on NF-кB
pathway.
Results: NTG induced the activation of oxidative stress and led to migraine in model animals, but pre-treatment
with VPA attenuated the damage due to migraine attack in brain tissues. The level of lipid peroxidation was
significantly reduced while the prodcution of anti-oxidant factors was restored. Furthermore, expressions of CGRP
and c-Fos, which represented the neuronal activation, were also down-regulated by VPA. The results of western
blotting and EMSA demonstrated that the above mentioned effect of VPA acted through the inhibition of NF-кB
pathway.
Conclusions: Although controversies on the effect of VPA on NF-кB pathway existed, our study revealed an
alternative mechanism of VPA in protecting against migraine, which would promote the development of
therapeutic strategies of migraine.
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Background
As a complicated nervous system disease, migraine is
characterized by the disability of components in the
trigeminal pain pathway. Patients with migraine are
attacked by disabling headache associated with sensi-
tivity to afferent inputs, including gastrointestinal inputs,
light, sound, and head movement [1]. Based on the inves-
tigation in 2002, over 20 % of the world population are
affected by migraine at some stage of their entire lives
[2], casting severe healthy and social issues to the pub-
lic health. Although the pathophysiological mechanism
which drives the onset of migraine remains poorly
understood, compelling evidence infers that nitric oxide
(NO) plays a critical role in the pathogenesis of mi-
graine [3–6]. The genes related to NO pathway, includ-
ing genes encoding endothelial NO synthase (eNOS),
inducible NO synthase (iNOS), and vascular endothelial
growth factor (VEGF) all increased patients’ susceptibil-
ity to migraine [3]. The pathways involved in the induc-
tion of migraine by NO may depend on the activation
of NF-кB [7], associated with the up-regulation of some
* Correspondence: zhongl_zhang67@sina.com
Department of Neurology, The First Affiliated Hospital of Harbin Medical
University, No. 23 Youzheng Road, Harbin 150001, People’s Republic of China
The Journal of Headache
                           and Pain
© 2016 Li et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
Li et al. The Journal of Headache and Pain  (2016) 17:49 
DOI 10.1186/s10194-016-0631-z
key molecules in neuronal activation, i.e., c-Fos [7, 8].
In the normal state, NF-кB is mainly located within the
cytoplasm and the subunits of NF-κB, p50 and p65,
are complexed with IκBα in an inactive form. Upon
stimulation, IκBα is degraded and free NF-κB sub-
units to enter the nucleus and subsequently cause the
expression of inflammatory genes which are the main
regulatory enzymes for NO [9]. Thus, some therapies
targeting these relevant pathways have been widely
investigated regarding their potential to attenuate the
damage caused by migraine [10, 11].
Among types of anti-migraine therapies, the protective
function of valproate (VPA) against migraine with mild
side effects has drawn lots of attention [12]. VPA is
achieved by reacting valproic acid (2-Propylpentanoic
acid) with a base such as sodium hydroxide and rapidly
absorbed in human bodies. VPA reaches peak plasma
concentration within one to four hours and thereafter
maintains the concentration for four to 14 hours [12]. In
clinic, VPA has been widely used as a treatment for
seizures and bipolar disorder. Additionally, in many ani-
mal models, VPA has improving effect on symptoms
associated with stroke, amyotrophic lateral sclerosis, Par-
kinson’s disease, and Alzheimer’s disease [13–16]. Regard-
ing migraine, researchers in Cochrane Collaboration have
affirmed the protective effect of VPA against this disorder
in their review in 2015 [12]. However, even with this solid
evidence that verifies the potential of VPA in antagonizing
migraine, few studies have explicitly revealed the pathways
which may be involved in this treatment process. There-
fore, the underlying mechanism which drives the action of
VPA on migraine remains poorly explained.
In this study, a rat migraine model was established via
intraperitoneal injection of nitroglycerin (NTG). As a
donor of NO, NTG has been successfully used as an
experimental agent to induce migraine in many studies
[3, 17, 18]. Administration of NTG can induce activation
of cGMP and NF-кB, and further lead to pathogenesis of
migraine [6, 19]. The electroencephalogram (EEG) of the
experimental animals and the synthesis of oxidative stress
molecules which are involved in numerous neurological
diseases [20] were detected to assess the effect of VPA on
the brain function. The expression of calcitonin gene-
related peptide (CGRP) which is closely related to the
migraine disorder and headache generation [21], and c-
Fos were measured using ELISA, immunohistochemistry,
and western blotting assay, respectively. To further explain
the pathways involved in the treatment of VPA, the activ-
ities of IκBα and NF-κB were determined with western
blotting assay and electrophoretic mobility shift assay
(EMSA). We hoped that our findings in the present study
would provide a preliminary explanation on the mechan-
ism of VPA against migraine and help to promote the
application of VPA in clinic.
Methods
Chemicals and animals
VPA was purchased from Melonepharma (Catal. No.
MB1627, Dalian, China) and dissolved in saline. NTG was
purchased from Yimin Pharmaceutical Co., Ltd (Catal.
No. H11021022, Beijing, China). Antibodies against c-Fos,
p65, IкBα, phosphorylated IкBα (p-IкBα), and Histone H3
were purchased from Beijing Biosynthesis Biotechnology
Co., LTD (Catal. No. bs-10172R, bs-5515R, bs-1287R, bs-
17422R, Beijing, China). Antibody against NF-кB subunit
p65 was purchased from Boster (Catal. No. BA0610.
China). Antibody against β-actin was purchased from Santa
Cruz Biotechnology, Inc. (Catal. No. sc-47778. USA). Vita-
min A standard was purchased from Sigma-Aldrich Co.
(Catal. No. R7632, St. Louis, MO, USA). Male Sprague-
Dawley rats (weighting ca. 200 g) were provided by Experi-
mental Animal Center of China Medical University. All the
animals were housed at 20-25 °C with humidity of 55 ± 5 %
and had free access to food and water before experimental
use. The animal experiments were conducted in accordance
with the Institutional Animal Ethics Committee and Ani-
mal Care Guidelines of The First Affiliated Hospital of
Harbin Medical University.
Migraine model establishment and pre-administration of
VPA
Fifty SD rats were randomly divided into five groups (ten
for each group): A) control group, SD rats received an
intraperitoneal injection of saline. B) VPAH group, SD rats
received intraperitoneal injection of 200 mg/(kg body
weight) VPA for five days; C) NTG group, SD rats re-
ceived intraperitoneal injection of vehicle of VPA each day
for five days followed by intraperitoneall injection of
10 mg/(kg body weight) NTG. D) NTG-VPAL group, SD
rats received intraperitoneal injection of 100 mg/(kg body
weight) VPA for five days followed by injection of 10 mg/
(kg body weight) NTG. E) NTG-VPAH group, SD rats
received intraperitoneal injection of 200 mg/(kg body
weight) VPA for five days followed by injection of 10 mg/
(kg body weight) NTG. Four hours after NTG injection,
three rats were randomly selected from each group for
electroencephalogram (EEG) recording and the left ani-
mals were sacrificed for sampling of peripheral blood in
jugular vessel and brain tissues.
Determination of the effect of VPA pre-treatment on the
oxidative stress response in brain tissues
The lipid peroxidation was measured with the thiobarbituric-
acid reaction with brain homogenate samples, which
was determined by comparing the absorption to the
standard curve of malondialdehyde (MDA) according
to the method proposed by Placer et al. [22] using MDA
detection kit according to the manufacturers’ instruction
(Catal. No. A003-1, Nanjing Jiangcheng Bioengineering
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Institute, Nanjing, China). Additionally, the activities of
glutathione (GSH) and glutathione peroxidase (GSH-x) in
brain homogenate samples were measured according to the
manufacturers’ introductions of the assay kits (Catal. No.
A006-2, A005, Nanjing Jiancheng Bioengineering Institute,
China). Moreover, the concentrations of vitamin A in brain
homogenate samples were quantified according to the pre-
viously described methods [23–25]. Level of vitamin C and
vitamin E in brain homogenate samples were measured
using detection kits according to the manufacturers’ intro-
duction (Catal. No. A009, A008, Nanjing Jiangcheng Bio-
engineering Institute, Nanjing, China).
Enzyme-linked immuno sorbent assay
The level of CGRP in jugular blood [26, 27] was deter-
mined with ELISA method using CGRP detection kit
(Catal. No. CEA876Ra USCN, China) according to the
manufacturer’s instructions. For jugular blood collection,
1 mL blood samples in each group was drawn from the
jugular vessel and stored in Eppendorf tubes containing
EDTA (1 mg/ml blood) and the protease inhibitor Apro-
tinin (0.55 TIU/ml blood).
Immunohistochemical detection
For immunohistochemical assay, sections were made
from trigeminal nucleus caudalis (TNC) tissues from
different groups and incubated at 60 °C overnight before
dewaxed with dimethylbenzene. The slides were hydrated
with alcohol followed by washed with H2O2 for 5 min,
fixed using methanol solution with 3 % H2O2, and blocked
with 1 % goat serum for 15 min at room temperature.
They were then incubated with primary anti-c-Fos anti-
body (1:200) at 37 °C for 30 min before incubated at 4 °C
overnight. After four cycles of 0.01 M PBS wash, 5 min for
each cycle, secondary antibody (1:200) was added to the
slides and placed at 37 °C for 30 min before another four
cycles of PBS wash. Slides were incubated with HRP at
37 °C for 30 min before three cycles of 5-min PBS
washing. Then DAB was added to the slides and reacted
for 3–10 min until the reaction was stopped by ddH2O.
Slides were re-stained using haematoxylin and dehydrated.
Percentage of positively stained cells and the staining
intensity of the different groups were determined by
observation under a microscope at 400× magnification by
experimenters blind to the experiments.
Western blotting assay
The protein product of c-Fos, IκBα, and p-IκBα in TNC
of different groups was extracted using the Total Protein
Extraction Kit according to the manufacturer’s instruc-
tions (Catalog No. WLA019, Wanleibio, China). Nuclear
NF-кB subunit p65 was extracted using Nuclear and
Cytoplasm Protein Extraction kit (Catal. No. WLA020,
Wanleibio, China). β-actin and Histone H3 were used as
internal reference proteins for different molecules. Con-
centrations of protein samples were determined using
the BCA method and western blotting was performed as
described previously with some modification [10]: 40 μg
protein in 20 μL volume was subjected to 10 % sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE). After transferring the proteins onto polyvinyli-
dene difluoride (PVDF) membranes, the membranes were
washed with TTBS for 5 min and then incubated with
skim milk powder solution for 1 h. Primary antibody
against c-Fos (1:500), IκBα (1:500), p-IκBα (1:500), and
nuclear NF-кB subunit p65 (1:400), β-actin (1:1000) or
Histone H3 (1:500) was added and the membranes
were incubated at 4 °C overnight. Following washing
with TTBS, the membranes were incubated with HRP-
conjugated IgG secondary antibodies (1:5000) for 45 min
at 37 °C. After washing, the blots were developed using
Beyo ECL Plus reagent and scanned in the Gel Imaging
System. The relative expression levels of the target pro-
teins were calculated with Gel-Pro-Analyzer (Media
Cybernetics, USA).
Electrophoretic Mobility Shift Assay (EMSA)
The nuclear protein in TNC samples were extracted
using Nuclear and Cytoplasm Protein Extraction kit (Catal.
No. WLA020, Wanleibio, China). The DNA binding ability
of NF-кB was quantified by EMSA using NF-кB EMSA kit
(Viagene, China) according to the manufacturer’s instruc-
tion: briefly, the TNC samples were diluted using PBS into
5 μg/μL and subjected to the reaction solution before
addition of biotin-labelled NF-кB probe. The blots were
developed using Beyo ECL Plus reagent and the results
were detected in the Gel Imaging System.
Statistical analysis
All the data were expressed in the form of mean ± SD
and n number for each analysis for each group was five.
Post-doc multiple comparisons were conducted by LSD
(least significant difference) method using general liner
model with a significant level of 0.05. All the statistical
analysis and graph manipulation were conducted using
R language version 3.2.1 [28].
Results
Results of EEG recording
Rats in control group had normal baseline EEGs without
any evidence of paroxysmal activity (Fig. 1a). The injec-
tion of NTG induced an increase of theta and delta
activity in EEG record (Fig. 1b). After administration of
VPA, the increase of the slow activity was restored to
relatively normal pattern. Moreover, the effect of VPA
on NTG-induced migraine was dose-dependent with the
EEG in VPAH group performing better than that in
VPAL group (Fig. 1c and Fig. 1d). However, there was
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no significant change in the amplitude of the EEG waves
in the four groups. Although our results didn’t provide
solid evidence in differentiating migraine from non-
migraine cases, it might suggest some difference in the
posterior background activity in the EEG in migraine
rats as compared to the controls.
Pre-administration of VPA improved the oxidative stress
response induced by NTG injection
Detecting results of MDA, GSH, GSH-x, vitamin A,
vitamin C, and vitamin E were shown in Table 1. It was
confirmed that sole treatment of VPA of 200 mk/(kg
body weight) had no effect on the expression of the
six indicators. MDA was representative of the lipid
peroxidation and the level was up-regulated by NTG
injection, indicating an increase in the lipid peroxida-
tion in brain tissues. Contrary to the change pattern
of MDA, the content of GSH and GSH-x were both
reduced by NTG injection (Table 1). GSH is the most
abundant thiol andioxidant in mammalian cells and
maintains the thiol redox in the cells. GSH-x is crit-
ical for the reduction of hydro- and organic peroxides
with the presence of GSH. The production of three
indicators was restored to relatively normal levels in the
VPA pre-treated groups, representing the anti-oxidation
effect of VPA on brain tissues. The effect of VPA on
NTG-induced dys-expression of the three indicators was
dose-dependent but there was no significant difference
Fig. 1 Effect of VPA on electroencephalogram records in brain of migraine-induced rats. a image representation of electroencephalogram in
control group; b image representation of electroencephalogram in NTG group; c image representation of electroencephalogram in NTG + VPAL
group; d image representation of electroencephalogram in NTG + VPAH group
Table 1 The effect of VPA on the oxidative stress response in NTG-induced migraine rats (mean ± SD)
Indicators Group
Control VPAH NTG NTG-VPAL NTG-VPAH
MDA (nmol/mg protein) 10.8 ± 1.9 8.5 ± 2.8 25.3 ± 6.7*,** 21.8 ± 4.2*,** 13.5 ± 3.5***,****
GSH (nmol/mg protein) 8.9 ± 1.2 8.4 ± 1.9 5.2 ± 0.9*,** 6.2 ± 1.5* 8.2 ± 1.5***
GSH-x (U/g protein) 17.8 ± 0.6 16.3 ± 3.4 7.8 ± 2.0*,** 10.8 ± 3.0*,** 15.1 ± 2.1***,****
Vitamin A (μmol/g brain) 3.3 ± 0.7 3.2 ± 0.5 1.6 ± 0.3*,** 2.1 ± 0.3*,** 2.9 ± 0.4***,****
Vitamin C (μmol/g brain) 71.0 ± 16.6 69.2 ± 11.7 33.8 ± 8.0*,** 44.0 ± 6.6*,** 62.5 ± 9.6***
Vitamin E (μmol/g brain) 11.0 ± 1.5 11.8 ± 2.0 5.8 ± 1.5*,** 7.4 ± 1.1*,** 9.0 ± 1.6***
“*”, significantly different from the control group, P < 0.05; “**”, significantly different from the VPAH group, P < 0.05; “***”, significantly different from the NTG
group, P < 0.05; “****”, significantly different from the NTG-VPAL group, P < 0.05
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between NTG and NTG-VPAL groups, and only the
difference between NTG group and NTG-VPAH group
was statistically significant (P < 0.05). The change patterns
of the content of vitamin A, vitamin C, and vitamin E in
different groups were similar to those of GSH and GSH-x
(Table 1), which was also indicative of the anti-oxidative
potential of VPA as well.
Pre-administration of VPA inhibited the increase of CGRP
level in jugular blood and reduced the number of c-Fos
positive neurons in TNC
As show in Fig. 2a, the synthesis of CGRP was also
induced by NTG injection, but pre-administration of
VPA suppressed the increase and the effect was dose-
dependent: the inhibiting effect of 200 mg/(kg body
weight) VPA on CGRP was stronger than that of 100 mg/
(kg body weight) dose, but only the level of CGRP in
NTG+VPAH group was significantly different from that
of NTG group (P < 0.05). The expression of c-Fos in TNC
was assessed using immunohistochemistry (Fig. 2b). c-Fos
positive neurons were determined as the brown granules
labeled in the cell nucleus. The NTG injection increased
the number of c-Fos positive neurons. In VPA pre-treated
groups, the densities of brown granules obviously reduced
under the observation with a microscope at 400× magnifi-
cation. Additionally, the expression of c-Fos production
illustrated by western blotting exhibited a similar pattern
to that of immunohistochemistry (Fig. 3a), and the levels
of c-Fos in both NTG+VPAL and NTG +VPAH groups
were significantly different from that of NTG group
(P < 0.05).
VPA protect brain tissue against the NTG-induced mi-
graine via the inhibition of NF-кB pathway
The expressions of protein product of IκBα, p-IκBα, and
NF-кB subunit p65 were quantified using western blot-
ting assay. Production of p-IκBα and nuclear NF-кB
subunit p65 was closely related to the activation of NF-
кB pathway. After the injection of NTG, it was found
the levels of these two molecules were up-regulated
(Fig. 3b and 3c), and the differences between control
groups and NTG groups were statistically significant
(P < 0.05). The activation of NF-кB pathway was also
verified by the increase of NF-кB’s DNA binding ability
detected by EMSA (Fig. 4). Opposite to the expression of
p-IκBα and p65, the expression of IκBα was inhibited by
NTG injection. IκBα in cytoplasm would bind to NF-кB
and inhibit its activation. Our results confirmed that
NTG-induced migraine could be initiated by the activa-
tion of the NF-кB pathway. Then pre-administration of
VPA reversed the expression pattern of NF-кB pathway
members due to migraine attack. Both doses of VPA sig-
nificantly reduced the expressions of p-IκBα and NF-кB
subunit p65 (Fig. 3b and 3c), and corresponding to the
decreased level of p65, the DNA binding activity of NF-кB
was also inhibited (Fig. 4). In addition, the level of cyto-
plasmic IκBα was restored by pre-administration of VPA.
The effect of VPA on the NF-кB pathway was dose-
dependent as well, and the difference between the two
doses of VPA was statistically significant (P < 0.05).
Discussion
Trigeminovascular system is believed to play a crucial
role in the attacks of migraine in classical neuroscience
field [29]. The signal that will finally lead to migraine is
transmitted to the ventroposterior thalamus from the
so-called trigeminocervical complex (or TNC) [30]. In
addition, central sensitization associated with activation
of NF-кB in the TNC is reported to be involved in the
pathogenesis of migraine as well [11]. NF-кB is believed
to be implicated in multiple signaling pathways in
variable physiological and pathological settings [31], and
numerous therapies targeting the NF-кB pathways has
been developed to protect patients against migraine
[7, 11]. The results of the current study showed that
pre-administration of VPA alleviated the impairments
due to NTG-induced migraine by inhibiting the acti-
vation of NF-кB signal transduction pathway.
Fig. 2 Pre-administration of VPA reduced the expression of CGRP
in jugular blood and the expression of c-Fos in trigeminal nucleus
caudalis. a quantitative analysis results of expression of CGRP in
different groups. “a”, significantly different from control group,
P < 0.05; “b”, significantly different from VPAH group, P < 0.05;
“c”, significantly different from NTG group, P < 0.05. b representative
images of immunohistochemical staining of c-Fos in different
groups, c-Fos positive neurons were stained brown
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Experimental models of migraine induced by NTG
injection reflect the inflammatory response with the
contribution to the activation of iNOS and cytokines at
the meningeal level [19]. Moreover, NTG is evidently
proved to trigger the activation of NF-кB in the TNC
[7]. In our findings, after injection of NTG, the level of
MDA in NTG group was significantly up-regulated com-
pared with control group. It is believed that oxidative
stress-induced lipid peroxidation is involved in numer-
ous neurological diseases including migraine [20]. Asso-
ciated with the increase of lipid peroxidation, significant
decrease in antioxidant effectors was also recorded. For
GSH and GSH-x, down-regulated of these two molecules
in NTG group represented an overload production of
reactive oxygen species (ROS) due to NTG-induced mi-
graine attack Also, levels of vitamin A, vitamin E, and
vitamin C, which are capable of inhibiting mitochondria-
induced ROS production [32], were also significantly
inhibited in the brain tissues The low levels of antioxidant
vitamins resulted from NTG injection would facilitate oxi-
dative damage in the experimental rats. All the expression
patterns of the above mentioned molecules were reversed
by the pre-treatment of VPA, evidently indicating the
anti-oxidant ability of VPA in migraine. Interestingly, the
antioxidant effect of VPA has been found in other re-
search models, including idiopathic epilepsy and primary
Fig. 3 Pre-administration of VPA inhibited the activation of NF-кB pathway. a quantitative analysis results and representative images of western
blotting of c-Fos; b quantitative analysis results and representative images of western blotting of NF-кB subunit p65; c quantitative analyses results
and representative images of western blotting of p-IкBα and IкBα. “a”, significantly different from control group, P < 0.05; “b”, significantly different
from VPAH group, P < 0.05; “c”, significantly different from NTG group, P < 0.05. “d”, significantly different from VPAL group, P < 0.05
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cultured rat cerebral cortical cells [33–35]. Therefore, we
speculated that the protective role of VPA in NTG-
induced migraine might be associated with its alleviative
effects on oxidative stress damages instead of inhibition of
trigeminal neuronal firing.
The migraine antagonizing capability of VPA was also
verified by the decrease of jugular blood CGRP which
inhibits the synaptic release of various neurotransmitters
and is closely related headache generation [26, 36]. Fur-
thermore, the decrease of c-Fos in TNC also supported
antioxidant effect of VPA. c-Fos is a sensitive marker of
neuronal activation following noxious stimulation, and
expression of c-Fos has been widely used to identify
areas of neuronal activation and to study neural corre-
lates of nociception as well [37]. As being reported pre-
viously, VPA has an inducing effect on g-aminobutyric
acid (GABA) in migraine [38]. GABA is a neutral amino
acid which binds to one of at least 2 receptor subtypes
[39, 40]. Metabolism of GABA is disordered during the
attack of migraine [41]. Previous study indicates that
administration of VPA restores brain GABA levels and
suppresses migraine related events in the cortex [42].
The induction in GABA by VPA results in the inhibition
of neuron activation [43], which might affect CGRP and
c-fos expression via central and/or peripheral sites of
action. However, more than a single GABAergic mech-
anism might influence the expression of CGRP and
c-fos. Thus, experiments targeting GABA based on neural
progenitor cells are prepared in our lab to comprehensively
explore the mechanism through which VPA exerts its func-
tion on CGRP and c-Fos.
The findings in the current study strongly suggested
the inductive effect of NTG on NF-кB. NF-кB is a tran-
scriptional factor that regulates the apoptosis and in-
flammation in various diseases [31]. The inactive form of
NF-кB is sequestered in the cytoplasm by binding with
IκBα. Once IκBα is phosphorylated into p-IκBα, NF-кB
subunits will be translocated into nucleus and activate
the transcriptional of the targeted genes. After being
treated with NTG, the expressions of p-IκBα and nuclear
NF-кB subunit p65 were all enhanced and further led to
the activation of NF-кB related pathways. To the opposite,
level of IκBα was reduced, which would further result in
the release of active form of NF-кB in cytoplasm. Com-
bined with the results of ELISA and immunohitochemical
detection, our study was in consistence with the emerging
studies that report the activity of NF-кB in regulating the
plasticity of neurons and synapsis [31, 44]. In the work of
Yin et al., the authors suggest that atorvastatin attenuated
the NTG-induced NF-кB activation in TNC in a dose-
dependent manner [11]. Furthermore, in the study of
Reuter et al., the results infer that NTG promotes NF-кB
activity and inflammation, and administration of parthe-
nolide can alleviate the impairment by deactivating the
activation of NF-кB and expression of iNOS [45]. Regard-
ing the effect of VPA on NF-кB pathway, Go et al. [46]
reported that VPA possesses the ability to inhibit neural
progenitor cell death via the activation of NF-кB. How-
ever, the results of Go’s study is exactly contrary to ours
which indicated that pre-treatment with VPA significantly
attenuated the activity of NF-кB pathways and led to the
protective effect on nervous system. Although many stud-
ies suggest that VPA inhibits NF-кB activity possibly by
increasing acetylation on NF-кB [46], at least one study
reports that VPA protects neuron from oxidative stress-
induced cell death by acetylation-induced activation of
NF-кB. Additionally, Rao and his colleague inferred that
VPA could inhibit the activation of NF-кB by decreasing
the p50 protein levels and had no effect on the phosphor-
ylation state of IкBα, level of total IкBα protein, or protein
level of cytosolic p65 in cytosol [47]. But in the current
study, solid evidence showed that VPA influenced the
activity of both IкBα and p65. These contradictions of the
effect of VPA on the NF-кB pathway has been raised by
several other studies as well [48–51], which suggest the
possibility that the differential regulating pattern of VPA
on NF-кB activity in different experimental conditions
may be due to the dose- and time window-sensitive char-
acteristics of VPA. Thus, the application of the VPA to
modulate NF-кB related pathways should be carefully
assessed before being brought into practice.
Fig. 4 Pre-administration of VPA inhibited the DNA biding ability
of NF-кB. “a”, significantly different from control group, P < 0.05;
“b”, significantly different from VPAH group, P < 0.05; “c”, significantly
different from NTG group, P < 0.05. “d”, significantly different from VPAL
group, P < 0.05
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Conclusions
In summary, our current work investigated the poten-
tial of VPA as a therapy against migraine. Based on a
NTG-induced migraine model, it was found that pre-
administration with VPA would alleviate the damage
due to migraine attack. Through the inhibition of NF-кB
pathway in TNC, VPA could reduce the production of
ROS in brain tissues. However, the explicit mechanism of
VPA acting on NF-кB pathway is still complex. Given the
contrary conclusions of ours and previous studies
[48–51], application of VPA in clinic should be care-
fully assessed based on certain conditions. What can
be told is that defining the role of VPA in protecting
against diseases such as migraine will provide more
insights into the pathogenesis and therapeutic strategies of
nervous system disorders.
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